TCR T-cell therapy (TScan Therapeutics)

N/A

Report date: 2025/06/11 11:23:57

Base Information

Drug NameTCR T-cell therapy (TScan Therapeutics)
Drug Alias Nameanti-target/HLA-A*02:01 TCR T-cell therapy (TScan Therapeutics)TSC-205TSC-205-A0201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsT lymphocytes stimulantsImmunostimulants
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A